

# CANCER GENOMICS & PROTEOMICS

online from January 2009  
 STANFORD UNIVERSITY

[www.cgp-journal.com](http://www.cgp-journal.com)  
Print ISSN: 1109-6535  
Online ISSN: 1790-6245  
VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)  
VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009) - VOL. 7 (2010)

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, \*DLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

## Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org) (Editorial Office); [editor@cgp-journal.com](mailto:editor@cgp-journal.com) (Managing Editor)

## A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (*Louisville KY, USA*)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (*Greenville; Chapel Hill, NC, USA*)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (*Cardiff, UK*)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Turin; Milan, Italy*)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Tucson, AZ; Redwood City, CA, USA; Haifa, Israel*)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*)

Inhibition of Prostaglandin E2 Production by Flavone and its Related Compounds. T. KANEKO, H. CHIBA, N. HORIE, T. KATO, M. KOBAYASHI, K. HASHIMOTO, K. KUSAMA, H. SAKAGAMI ( <i>Tokyo; Saitama, Japan</i> ) .....	55
Comparison of the Effect of Orally Administered Soluble $\beta$ -(1-3),(1-6)-D-Glucan and of G-CSF on the Recovery of Murine Hematopoiesis. U. HARNACK, K. ECKERT, I. FICHTNER, G. PECHER ( <i>Berlin, Germany</i> ) .....	59
Comparison of Lipid Profiles in Relation to <i>APOB</i> EcoRI Polymorphism in Obese Children with Hyperlipidemia. O. TİMİRCİ, F. DARENDELİLER, F. BAS, E.H. ARZU, Z. UMİT, T. ISBİR ( <i>Istanbul, Turkey</i> ) .....	65
CYP17 (T-34C) and CYP19 (Trp39Arg) Polymorphisms and their Cooperative Effects on Breast Cancer Susceptibility. B.M. TÜZÜNER, T. ÖZTÜRK, H.I. KISAKESEN, §. İLVAN, C. ZERRİN, O. ÖZTÜRK, T. İSBİR ( <i>Istanbul, Turkey</i> ) .....	71
Relationship between Psychoncology and Psychoneuroendocrinology (PNEI): Enhanced T-Regulatory Lymphocyte Activity in Cancer Patients with Self-punishment, Evaluated by Rorschach Test. G. MESSINA, P. LISSONI, E. BARTOLACELLI, L. MAGOTTI, M. CLERICI, P. MARCHIORI, E. COLOMBO ( <i>Milan, Italy</i> ) .....	75
<i>Clinical Studies</i>	
Treatment of Peritoneal Carcinomatosis from Colonic Cancer by Cytoreduction, Peritonectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Experience of Ten Years. M. VAIRA, T. CIOPPA, S. D'AMICO, G. DE MARCO, M. D'ALESSANDRO, G. FIORENTINI, M. DE SIMONE ( <i>Empoli, Florence, Italy</i> ) .....	79
Familial Chronic Lymphocytic Leukemia in Norway and Denmark. Comments on Pleiotropy and Birth Order. V. JØNSSON, G.E. TJØNNFJORD, T.B. JOHANNESEN, B. LY, J.H. OLSEN, M. YUILLE ( <i>Oslo, Norway; Copenhagen, Denmark; Manchester, UK</i> ) .....	85
* Review: Radioguided Surgery and Systemic Radionuclide Therapy of Neuroendocrine Tumours. M. HODOLIČ, J. FETTICH, M.C. MARZOLA, E. TONINI, A. AL-NAHHAS, D. RUBELLO ( <i>Ljubljana, Slovenia; Rovigo, Italy; London, UK</i> ) .....	97
CX32 and CX43 Expression to Cytoplasmic Pattern During Colorectal Carcinogenesis. L. KANCZUGA-KODA, M. KODA, S. SULKOWSKI, A. WINCEWICZ, B. ZALEWSKI, M. SULKOWSKA ( <i>Bialystok, Poland</i> ) .....	101
Synchronous Presentation of GISTs and Other Primary Neoplasms: A Single Center Experience. N. ARNOGIANNAKI, I. MARTZOUKOU, P. KOUNTOURAKIS, E. DIMITRIADIS, A. PAPATHANASAKI, E. NASTOULIS, M. GAZALIDOU, A. FIDA, N. APOSTOLIKAS, N.J. AGNANTIS ( <i>Athens; Ioannina, Greece; Houston, TX, USA</i> ) .....	109
Immune Response Parameters During Labor and Early Neonatal Life. E. PROTTONOTARIOU, C. CHRELIAS, D. KASSANOS, H. KAPSAMBELI, T. EFTIHIOS, A. SARANDAKOU ( <i>Thessaloniki; Athens, Greece</i> ) .....	117

\* Review (page 97)